HealthCare Global Enterprises announced a proposed rights issue of up to 8,294,566 fully paid-up equity shares at an Issue Price of ₹512.00 per share. The Issue Price includes a premium of ₹502.00 per share. The Record Date for determining eligible shareholders is set for Monday, March 2, 2026, with the Issue Opening Date slated for Wednesday, March 11, 2026.
Rights Issue Overview and Price Structure
HealthCare Global Enterprises Limited has detailed its proposal to raise capital through a rights issue directed exclusively at its Eligible Equity Shareholders. The company plans to issue up to 8,294,566 fully paid-up Equity Shares with a face value of ₹10.00 each.
The subscription price for these Rights Equity Shares is set at ₹512.00 per share, which incorporates a significant premium of ₹502.00. The total aggregate amount anticipated from this Issue, assuming full subscription, is approximately ₹42,468.18 lakhs.
The entitlement ratio for the Issue is established at 1 (one) Rights Equity Share for every 17 (seventeen) Equity Shares held by the Eligible Equity Shareholders as of the designated Record Date.
Key Dates for the Rights Issue
The successful execution of the Issue relies on adherence to the following critical timeline:
- Last Date for Credit of Rights Entitlements: Wednesday, March 4, 2026
- Issue Opening Date: Wednesday, March 11, 2026
- Last Date for On-Market Renunciation: Friday, March 20, 2026
- Issue Closing Date: Wednesday, March 25, 2026
- Finalisation of Basis of Allotment (On or About): Friday, March 27, 2026
- Date of Allotment (On or About): Friday, March 27, 2026
- Date of Credit of Rights Equity Shares (On or About): Monday, March 30, 2026
- Date of Listing (On or About): Wednesday, April 1, 2026
Intended Use of Net Proceeds
The Net Proceeds, estimated at approximately ₹41,960.83 lakhs after deducting Issue-related expenses, are earmarked for strategic deployment across three primary areas. The deployment schedule shows that the funds will be utilized across Financial Year 2027 as planned.
The utilization plan is detailed as follows:
- Pre-payment/Repayment of Outstanding Borrowings: An estimated ₹17,000.00 lakhs will be used for repaying or prepaying outstanding borrowings, including those of the wholly-owned Subsidiary, HCG NCHRI Oncology LLP.
- Acquisition Consideration: Approximately ₹15,403.96 lakhs is allocated for the part-payment of consideration to acquire an additional 34.00% stake in Vizag Hospital and Cancer Research Center Private Limited (VHCRCPL).
- General Corporate Purposes: The remaining balance, approximately ₹9,556.87 lakhs, will be utilized for general corporate purposes, provided this amount does not exceed 25% of the Gross Proceeds.
Promoter Participation Intentions
Key stakeholders within the Promoter and Promoter Group have confirmed strong commitment to the Issue. Hector Asia Holdings II Pte. Ltd. intends to subscribe to the full extent of its Rights Entitlements and may also seek to subscribe to additional Rights Equity Shares if available, ensuring compliance with minimum public shareholding norms.
Similarly, Promoter Catalyst Trusteeship Limited also intends to subscribe fully to its entitlements and may participate in the unsubscribed portion. Promoter Dr. B S Ajaikumar intends to subscribe fully to his entitlements, with minor exceptions for inter se renunciation within the promoter group.
Financial Health and Risk Factors Summary
The company noted that for the nine months ended December 31, 2025, Total Income was ₹189,308.00 lakhs, with a Profit After Tax of ₹1,874.00 lakhs. For the full Financial Year ended March 31, 2025, Total Income was ₹222,285.00 lakhs, and Profit After Tax was ₹4,883.00 lakhs.
The document highlights several material risks, including dependency on obtaining and retaining necessary licenses and approvals for operations, potential disruptions from IT system failures or cyber attacks, and exposure to fluctuations in the value of the Indian Rupee given significant capital expenditure on USD-denominated equipment. Furthermore, a majority of centers operate on leased premises, posing risks upon lease renewal.
Tax Benefits Overview
The expert tax opinion outlined potential direct tax benefits for the Company and its Material Subsidiary under the Income Tax Act, 1961, including the option to opt for a concessional tax rate of 22% under Section 115BAA, provided certain exemptions are not availed. The report also notes the availability of deductions related to the employment of new staff (Section 80JJAA) and amortization of amalgamation expenses (Section 35DD).
Application Process and Compliance
All Investors are mandatorily required to use the ASBA process for making applications, whether through a Designated Branch of a SCSB or electronically. Applicants must ensure their Depository Participant (DP) ID, Client ID, and PAN details are correct and match records to avoid rejection. Furthermore, Rights Entitlements must be dealt with in dematerialized form only.
Source: BSE
